Rami Manochakian

Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.

Rami Manochakian, Associate Professor and Hematology/Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:

“Hot off the press.

Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative Exclaim2 trial.”

 

Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.

For deteils click here.
Source: Rami Manochakian/Twitter

cancer Lung cancer Mayo Clinic Mobocertinib OncoDaily Oncology Rami Manochakian